Supplementary Table 3: Joinpoint regression of regional mortality trends

| Country | Sex | CauseCategory | Breakpoint 1 (95% CI) | Breakpoint 2 (95% CI) | AAPC 1 (%) (95% CI) | AAPC 2 (%) (95% CI) | AAPC 3 (%) (95% CI) | AAPC Total (%) (95% CI) | Cumulative change (%) (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CZE | Men | All | 2009 (1998.7, 2019.9) | - | -1.9\* (-2.3, -1.5) | -1.6\* (-2.0, -1.2) | - | -1.8\* (-1.9, -1.6) | -28.6\* (-31.2, -25.9) |
| CZE | Men | Cancer | 2009 (1995.5, 2022.0) | - | -1.8\* (-2.3, -1.2) | -2.0\* (-2.4, -1.6) | - | -1.9\* (-2.1, -1.7) | -30.7\* (-33.4, -27.9) |
| CZE | Men | Cardiovascular | 2011 (2007.5, 2015.1) | - | -2.8\* (-3.1, -2.4) | -3.7\* (-4.3, -3.0) | - | -3.1\* (-3.4, -2.9) | -45.5\* (-47.7, -43.2) |
| CZE | Men | External | - | - | - | - | - | -2.0\* (-2.2, -1.8) | -31.7\* (-34.2, -29.1) |
| CZE | Men | Other | 2010 (2003.0, 2016.1) | - | 1.8\* (1.2, 2.4) | 2.4\* (1.8, 2.9) | - | 2.1\* (1.8, 2.3) | 47.5\* (40.6, 54.7) |
| CZE | Women | All | - | - | - | - | - | -1.9\* (-2.0, -1.8) | -30.3\* (-32.0, -28.6) |
| CZE | Women | Cancer | - | - | - | - | - | -1.5\* (-1.7, -1.4) | -25.7\* (-27.7, -23.6) |
| CZE | Women | Cardiovascular | 2005 (2004.1, 2006.4) | - | -0.7 (-1.8, 0.4) | -4.0\* (-4.2, -3.7) | - | -3.1\* (-3.3, -2.9) | -44.9\* (-47.2, -42.6) |
| CZE | Women | External | 2009 (2006.4, 2011.0) | - | -3.9\* (-4.7, -3.1) | -1.9\* (-2.5, -1.3) | - | -2.8\* (-3.1, -2.5) | -41.8\* (-45.2, -38.2) |
| CZE | Women | Other | 2009 (2006.4, 2012.3) | - | 1.6\* (0.9, 2.4) | 3.2\* (2.6, 3.8) | - | 2.4\* (2.1, 2.7) | 57.8\* (49.5, 66.5) |
| EST | Men | All | 2005 (1995.1, 2014.6) | - | -1.9 (-4.3, 0.6) | -2.7\* (-3.1, -2.2) | - | -2.5\* (-2.9, -2.1) | -37.8\* (-42.4, -32.8) |
| EST | Men | Cancer | 2006 (2002.7, 2010.2) | - | 0.8 (-0.1, 1.8) | -0.2 (-0.7, 0.2) | - | 0.2 (-0.1, 0.4) | 2.7 (-2.2, 7.8) |
| EST | Men | Cardiovascular | 2008 (2003.2, 2012.2) | - | -2.3\* (-3.9, -0.6) | -4.2\* (-5.5, -3.0) | - | -3.4\* (-4.0, -2.8) | -44.1\* (-49.9, -37.8) |
| EST | Men | External | 2002 (1995.2, 2009.7) | - | -4.1 (-9.7, 1.7) | -5.4\* (-5.9, -4.9) | - | -5.2\* (-5.8, -4.7) | -59.9\* (-63.6, -55.8) |
| EST | Men | Other | 2014 (2010.7, 2016.5) | - | -3.1\* (-4.1, -2.1) | 3.2 (-5.5, 12.8) | - | -1.9\* (-3.1, -0.7) | -27.8\* (-41.1, -11.5) |
| EST | Women | All | - | - | - | - | - | -2.7\* (-2.8, -2.5) | -40.0\* (-42.0, -38.0) |
| EST | Women | Cancer | - | - | - | - | - | -0.1 (-0.3, 0.1) | -2.0 (-5.5, 1.6) |
| EST | Women | Cardiovascular | 2004 (2000.1, 2007.7) | - | -2.2 (-4.4, 0.1) | -3.7\* (-4.0, -3.4) | - | -3.3\* (-3.7, -3.0) | -43.9\* (-47.0, -40.7) |
| EST | Women | External | 2004 (1991.2, 2016.0) | 2008 (1994.7, 2022.0) | -5.1 (-12.2, 2.5) | -6.7\* (-10.2, -3.0) | -5.7\* (-7.8, -3.5) | -5.8\* (-7.0, -4.7) | -64.0\* (-70.7, -55.7) |
| EST | Women | Other | 2006 (2003.9, 2007.7) | 2012 (2010.9, 2014.0) | -0.6 (-3.7, 2.6) | -6.9\* (-8.9, -5.0) | 2.7 (-2.4, 8.0) | -2.3\* (-3.3, -1.3) | -32.5\* (-43.4, -19.6) |
| LTU | Men | All | 2015 (2009.4, 2020.5) | - | -1.2\* (-2.1, -0.3) | -1.8\* (-2.7, -0.8) | - | -1.4\* (-1.9, -1.0) | -12.3\* (-15.6, -8.8) |
| LTU | Men | Cancer | 2012 (1997.7, 2026.4) | - | -0.2 (-2.6, 2.4) | 0.1 (-0.5, 0.7) | - | 0.0 (-0.5, 0.5) | 0.2 (-4.1, 4.7) |
| LTU | Men | Cardiovascular | - | - | - | - | - | -1.6\* (-2.0, -1.2) | -13.4\* (-16.5, -10.1) |
| LTU | Men | External | - | - | - | - | - | -4.4\* (-5.0, -3.7) | -33.0\* (-36.8, -29.0) |
| LTU | Men | Other | - | - | - | - | - | 1.3\* (0.7, 1.9) | 12.2\* (6.3, 18.3) |
| LTU | Women | All | 2014 (2007.9, 2020.9) | - | -1.4\* (-2.1, -0.7) | -1.0\* (-1.8, -0.3) | - | -1.2\* (-1.6, -0.9) | -10.5\* (-13.1, -7.8) |
| LTU | Women | Cancer | 2014 (2000.3, 2028.7) | 2017 (2006.8, 2026.9) | 1.6\* (0.4, 2.8) | 1.3 (-2.0, 4.8) | 1.9 (-1.0, 5.0) | 1.6\* (1.0, 2.3) | 15.5\* (9.1, 22.3) |
| LTU | Women | Cardiovascular | - | - | - | - | - | -2.1\* (-2.5, -1.7) | -17.4\* (-20.4, -14.4) |
| LTU | Women | External | 2015 (2009.8, 2020.0) | - | -2.2\* (-4.4, -0.0) | -0.9 (-3.1, 1.3) | - | -1.6\* (-2.7, -0.6) | -13.8\* (-21.7, -5.1) |
| LTU | Women | Other | - | - | - | - | - | 3.0\* (2.3, 3.6) | 29.9\* (23.0, 37.2) |
| POL | Men | All | 2014 (2010.3, 2018.1) | - | -1.9\* (-2.2, -1.7) | -1.4\* (-2.1, -0.7) | - | -1.7\* (-1.9, -1.6) | -20.4\* (-22.3, -18.4) |
| POL | Men | Cancer | 2011 (2008.2, 2013.0) | - | -1.2\* (-1.8, -0.5) | -0.3\* (-0.6, -0.1) | - | -0.6\* (-0.8, -0.4) | -7.8\* (-10.0, -5.6) |
| POL | Men | Cardiovascular | 2013 (2010.2, 2015.1) | - | -2.0\* (-2.6, -1.5) | -3.1\* (-3.6, -2.6) | - | -2.6\* (-2.8, -2.3) | -28.7\* (-30.9, -26.4) |
| POL | Men | External | - | - | - | - | - | -3.0\* (-3.3, -2.7) | -32.8\* (-35.2, -30.3) |
| POL | Men | Other | 2013 (2011.5, 2013.6) | - | -1.5\* (-2.4, -0.7) | 2.3\* (1.5, 3.1) | - | 0.3 (-0.0, 0.7) | 4.6 (-0.2, 9.7) |
| POL | Women | All | 2013 (2010.6, 2014.5) | - | -1.9\* (-2.2, -1.6) | -1.1\* (-1.4, -0.8) | - | -1.5\* (-1.7, -1.4) | -18.0\* (-19.6, -16.4) |
| POL | Women | Cancer | 2014 (2011.2, 2016.5) | - | -0.3 (-0.7, 0.1) | 0.6 (-0.1, 1.3) | - | 0.1 (-0.2, 0.3) | 0.7 (-2.5, 3.9) |
| POL | Women | Cardiovascular | 2013 (2010.4, 2016.5) | - | -2.4\* (-2.9, -2.0) | -3.3\* (-4.0, -2.6) | - | -2.8\* (-3.0, -2.6) | -30.9\* (-33.1, -28.5) |
| POL | Women | External | 2015 (2009.1, 2020.8) | - | -3.1\* (-3.6, -2.6) | -2.4\* (-4.0, -0.8) | - | -2.9\* (-3.3, -2.5) | -31.7\* (-35.3, -27.8) |
| POL | Women | Other | 2013 (2011.6, 2013.8) | - | -0.7 (-1.6, 0.2) | 3.1\* (2.3, 3.9) | - | 1.1\* (0.8, 1.5) | 15.7\* (10.3, 21.4) |
| ROU | Men | All | 2011 (2008.7, 2014.0) | - | -1.9\* (-2.1, -1.6) | -1.1\* (-1.5, -0.7) | - | -1.6\* (-1.7, -1.4) | -25.7\* (-27.5, -23.8) |
| ROU | Men | Cancer | 2016 (2011.6, 2019.5) | - | 1.1\* (0.8, 1.3) | -0.2 (-2.4, 2.1) | - | 0.8\* (0.6, 1.1) | 17.1\* (11.0, 23.6) |
| ROU | Men | Cardiovascular | 2011 (2007.1, 2014.1) | - | -2.6\* (-3.0, -2.2) | -1.7\* (-2.2, -1.1) | - | -2.2\* (-2.4, -2.0) | -34.6\* (-37.0, -32.0) |
| ROU | Men | Other | 2012 (2010.2, 2012.8) | - | -1.4\* (-1.9, -1.0) | 1.9\* (1.1, 2.8) | - | -0.1 (-0.4, 0.2) | -2.2 (-7.1, 2.9) |
| ROU | Women | All | 2012 (2009.0, 2014.0) | - | -2.4\* (-2.6, -2.1) | -1.5\* (-1.9, -1.1) | - | -2.0\* (-2.2, -1.9) | -32.2\* (-33.9, -30.4) |
| ROU | Women | Cancer | 2005 (1991.8, 2018.0) | - | 0.0 (-1.9, 1.9) | 0.4\* (0.2, 0.7) | - | 0.3\* (0.0, 0.6) | 6.5\* (0.5, 12.9) |
| ROU | Women | Cardiovascular | 2011 (2005.2, 2016.8) | - | -2.8\* (-3.2, -2.3) | -2.1\* (-2.8, -1.5) | - | -2.5\* (-2.7, -2.3) | -38.2\* (-41.0, -35.3) |
| ROU | Women | Other | 2010 (2009.1, 2011.6) | - | -1.4\* (-2.0, -0.8) | 2.4\* (1.6, 3.2) | - | 0.3\* (0.0, 0.6) | 6.0\* (0.3, 12.0) |
| SVK | Men | All | 2007 (2004.0, 2010.6) | - | -1.2\* (-1.8, -0.5) | -2.2\* (-2.5, -1.9) | - | -1.8\* (-2.0, -1.6) | -29.1\* (-31.8, -26.3) |
| SVK | Men | Cancer | 2005 (1993.3, 2017.4) | - | -1.0 (-1.9, 0.0) | -0.7\* (-0.9, -0.5) | - | -0.8\* (-1.0, -0.6) | -13.8\* (-17.1, -10.4) |
| SVK | Men | Cardiovascular | 2006 (2004.6, 2008.1) | - | -1.1 (-2.1, 0.1) | -3.7\* (-4.1, -3.3) | - | -2.8\* (-3.1, -2.5) | -41.9\* (-44.9, -38.7) |
| SVK | Men | External | 2007 (2000.2, 2013.3) | - | -0.8 (-2.2, 0.7) | -1.8\* (-2.3, -1.2) | - | -1.4\* (-1.8, -1.0) | -23.8\* (-29.2, -18.0) |
| SVK | Men | Other | 2010 (1993.2, 2027.7) | - | 0.0 (-0.6, 0.6) | -0.2 (-1.0, 0.5) | - | -0.1 (-0.4, 0.2) | -2.0 (-7.3, 3.6) |
| SVK | Women | All | 2006 (2001.9, 2009.4) | - | -1.1\* (-2.0, -0.2) | -1.9\* (-2.1, -1.7) | - | -1.7\* (-1.9, -1.5) | -27.6\* (-30.2, -24.9) |
| SVK | Women | Cancer | - | - | - | - | - | -0.1 (-0.3, 0.1) | -1.2 (-4.7, 2.5) |
| SVK | Women | Cardiovascular | 2005 (2003.9, 2006.9) | - | -0.8 (-2.1, 0.5) | -3.6\* (-3.9, -3.3) | - | -2.8\* (-3.1, -2.6) | -41.9\* (-44.8, -38.9) |
| SVK | Women | External | 2003 (1992.5, 2014.3) | - | -0.1 (-5.6, 5.8) | 1.1\* (0.5, 1.6) | - | 0.9\* (0.2, 1.5) | 17.7\* (3.5, 33.8) |
| SVK | Women | Other | 2010 (2000.4, 2019.3) | - | 0.7 (-0.0, 1.4) | 0.2 (-0.5, 0.8) | - | 0.5\* (0.1, 0.8) | 8.9\* (2.6, 15.6) |